Diabetes, Obesity and Metabolism

Edited by:
R. Donnelly, A. Garber and I. Caterson

ISI Journal Citation Reports® Ranking: 2008: 23/93 Endocrinology & Metabolism
Impact Factor: 4.259

The only interdisciplinary journal for high-quality research and reviews in the areas of diabetes, obesity and metabolism.

Diabetes, Obesity & Metabolism is primarily a journal of clinical and experimental pharmacology and therapeutics covering the interrelated areas of diabetes, obesity and metabolism. The journal prioritises high-quality original research that reports on the effects of new or existing therapies, including dietary, exercise and lifestyle (non-pharmacological) interventions, in any aspect of metabolic and endocrine disease, either in humans or animal and cellular systems. 'Metabolism' may relate to lipids, bone and drug metabolism, or broader aspects of endocrine dysfunction. Preclinical pharmacology, pharmacokinetic studies, meta-analyses and those addressing drug safety and tolerability are also highly suitable for publication in this journal. Original research may be published as a main paper or as a research letter.

TopNews and Announcements

Free Access in the Developing World
Free online access to this journal is available within institutions in the developing world through the HINARI initiative with the World Health Organization (WHO).

Articles published online ahead of print
Articles which have been fully copy-edited and peer-reviewed are published online through our OnlineEarly feature before the print edition of this journal is published.

NIH Public Access Mandate
For those interested in the Wiley-Blackwell policy on the NIH Public Access Mandate, please visit our policy statement.

TopHighlights

Enjoy free access to these highly cited articles

Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial

Adiponectin - a key adipokine in the metabolic syndrome

Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study)

Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes

Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus

Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study

Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes

Effect of early addition of rosiglitazone to sulphonylurea therapy in older type 2 diabetes patients (> 60 years): the Rosiglitazone Early vs. SULphonylurea Titration (RESULT) study

Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICTIVE study